Is Strattera a Stimulant? How Atomoxetine Compares With Intuniv, Qelbree, and the Other Alternatives

Why the question gets asked

Strattera gets called a stimulant for two reasons. It treats the same condition the stimulants treat, and it raises norepinephrine, which is one of the two neurotransmitters the stimulants raise. Neither makes it a stimulant. Amphetamine and methylphenidate act on the dopamine transporter and produce the reinforcing, peak-and-trough effect that earned them Schedule II status. Atomoxetine blocks norepinephrine reuptake, has little direct action at the dopamine transporter outside the prefrontal cortex, produces no euphoria at any studied dose, and is sold without a controlled-substance prescription. The FDA approved it in November 2002 as the first non-stimulant treatment for ADHD, and a generic has been available since 2017.

The comparison that matters is with the other non-stimulants, because that is the decision a patient or parent usually faces: the stimulant is off the table, or has failed, and three or four alternatives remain. I've written separately on whether non-stimulants work at all. This post is narrower. It takes atomoxetine and sets it against guanfacine (Intuniv), viloxazine (Qelbree), clonidine (Kapvay), and, for calibration, the stimulants.

The comparison at a glance

Effect sizes are standardized mean differences from the Cortese et al. 2018 network meta-analysis (Lancet Psychiatry, 5:727-738), clinician-rated core symptoms at roughly 12 weeks, 133 randomized trials. They are placebo-subtracted and are not head-to-head results; confidence intervals overlap for the non-stimulants. Viloxazine was approved after the analysis was published.

What atomoxetine does, and what it doesn't

Atomoxetine raises norepinephrine across the brain and raises dopamine in the prefrontal cortex specifically, because in that region the norepinephrine transporter handles dopamine clearance too. In the striatum and nucleus accumbens, where the reinforcing effects of stimulants originate, atomoxetine has little effect on dopamine. That regional selectivity is the pharmacological reason it improves attention and executive function without producing the reward signal that makes amphetamine a controlled substance. Given that profile, atomoxetine is the usual first choice in ADHD patients with an active or recent substance use disorder, and in households where a Schedule II drug cannot safely be kept.

The cost of that profile is a smaller and slower effect. Across the trials in Cortese 2018, atomoxetine's effect size in children was about 0.56, roughly half the amphetamine figure. In my practice the practical translation is this: a child who is markedly impaired on a stimulant-free day will likely still be noticeably impaired on a good atomoxetine day, though less so. A child whose impairment is moderate and whose main difficulty is sustained attention in class may do well enough that nobody needs a stimulant. The difference is not subtle, and families should hear it before the first dose rather than after the eighth week.

The second cost is time. Registration trials measured outcomes at six to ten weeks, and the curve keeps rising through that window. Stopping at three weeks because "it's doing nothing" is the most common way atomoxetine fails in the community. The comparison I use with parents is an SSRI for anxiety: the medicine is accumulating its effect for weeks before the effect is obvious, and judging it early is judging a race at the first turn.

Strattera vs Intuniv

This is the comparison parents ask about most, and it is the one where the two drugs differ most in kind. Guanfacine is an alpha-2A agonist. It calms the noradrenergic system rather than amplifying it, which is why its side effects are sedation and low blood pressure rather than insomnia and a racing heart. It reaches its effect faster than atomoxetine, usually within two to four weeks, and its benefit is weighted toward the hyperactive, impulsive, and emotionally reactive side of ADHD.

Three clinical facts decide most cases:

• Symptom profile. Inattention with anxiety points toward atomoxetine. Hyperactivity, impulsivity, irritability, aggression, or sleep-onset difficulty points toward guanfacine, which is also used off-label for tics and has evidence in ADHD with comorbid tic disorders.
• Age. Intuniv is approved for ages 6 to 17 only. Atomoxetine is approved through adulthood, with an adult effect size of about 0.45.
• Combination with a stimulant. Intuniv is the only non-stimulant with an FDA-approved adjunctive indication alongside a stimulant, and it is commonly used that way: the stimulant handles the daytime core symptoms, the guanfacine smooths the late afternoon and the evening. Atomoxetine plus a stimulant is used but is off-label and additive on heart rate and blood pressure.

On the numbers, guanfacine's effect size in children (about 0.67) edged atomoxetine's (about 0.56) in Cortese 2018, but the confidence intervals overlapped and the outcome measure was total symptoms. Importantly, guanfacine must be tapered rather than stopped, since abrupt discontinuation can produce rebound hypertension. Atomoxetine can be stopped without a taper.

Strattera vs Qelbree

Viloxazine extended-release, sold as Qelbree, is the closest relative atomoxetine has. Both inhibit norepinephrine reuptake, both are non-controlled, and both carry a boxed warning for suicidal thoughts in young people. Viloxazine was an antidepressant in Europe for decades before Supernus reformulated it for ADHD; the FDA approved it for ages 6 to 17 in April 2021 and for adults in April 2022.

Four differences matter at the prescribing desk:

• Onset. Viloxazine's pediatric trials showed separation from placebo by week one or two on some measures, earlier than atomoxetine's typical four-to-eight-week course. Full effect still takes several weeks.
• Metabolism. Atomoxetine depends on CYP2D6. Roughly 7 percent of people of European ancestry are poor metabolizers and reach several-fold higher blood levels at the same dose; patients on fluoxetine, paroxetine, or bupropion are effectively converted into poor metabolizers. Viloxazine does not use CYP2D6, so that particular problem disappears. However, viloxazine is a strong CYP1A2 inhibitor, which means caffeine, duloxetine, clozapine, and theophylline levels rise, and a teenager drinking energy drinks on viloxazine may feel it.
• Evidence base. Atomoxetine has more than twenty years of post-marketing data, including long-term growth, cardiovascular, and hepatic safety, and an adult indication studied in multiple trials. Viloxazine has the registration program and a few years of real-world use.
• Cost. Generic atomoxetine is inexpensive. Qelbree is brand-only, and most insurers require a documented trial of a generic alternative first, which in practice often means atomoxetine.

The honest summary is that viloxazine is atomoxetine with a different interaction profile and a faster start, at brand-name cost and with a shorter safety record. For a patient who failed atomoxetine because of nausea or because they are a CYP2D6 poor metabolizer, viloxazine is a reasonable next step. For a patient who never tried atomoxetine, there is rarely a reason to skip it.

The other alternatives

Clonidine extended-release (Kapvay). Approved in 2010 for ages 6 to 17, as monotherapy or adjunct. Pharmacologically close to guanfacine but less selective, more sedating, and with a shorter half-life. Its effect size in Cortese 2018 was about 0.71 in children, in the same band as guanfacine. It is chosen over guanfacine mainly when sedation at bedtime is the goal rather than a side effect.

Bupropion. Off-label. In adults its effect size was about 0.46 in Cortese 2018, similar to atomoxetine's adult figure. It is an option when depression and ADHD coexist, with the caveat that it inhibits CYP2D6 and therefore cannot be combined casually with atomoxetine.

Centanafadine (Simtriyo). Approved in July 2026 and classified by the FDA as a stimulant despite its norepinephrine-dominant profile. I've covered its trial numbers separately; its effect sizes (0.24-0.40) sit below atomoxetine's, and it is not yet in pharmacies.

Stimulants. For calibration, methylphenidate's effect size in children was about 0.78 and amphetamine's about 1.02. For the patient who has tried a non-stimulant and is still impaired, and who has no contraindication, the right alternative is usually a carefully titrated stimulant rather than a second non-stimulant. I cover the titration logic on the titration page and the medication families on the medication guide.

Who atomoxetine is for

Consistent with its pharmacology and the trial data, atomoxetine is the first choice in a defined set of patients:

1. ADHD with a comorbid anxiety disorder, where stimulants can worsen the anxiety and atomoxetine has trial evidence of improving both.
2. ADHD with an active or recent substance use disorder, or a household where a Schedule II medication cannot be secured.
3. ADHD with a tic disorder, where stimulants are usable but sometimes blamed for tic exacerbation; atomoxetine reduced tics modestly in one controlled trial.
4. Patients who need 24-hour coverage, including early morning and late evening, because atomoxetine has no wear-off.
5. Patients who could not tolerate two stimulant classes because of insomnia, appetite loss, or mood flattening.

It is a poor first choice when impairment is severe and immediate function is at stake (a student mid-semester, an adult whose job is in jeopardy), when the family cannot commit to the eight-week window, or when the patient is a known CYP2D6 poor metabolizer on a dose that was not adjusted.

Safety: the boxed warning and the liver

In 2005 the FDA added a boxed warning to atomoxetine after a pooled analysis of twelve pediatric trials found suicidal ideation in 0.4 percent of atomoxetine-treated children and none in the placebo group (5 of 1,357 versus 0 of 851). No suicides occurred. The signal is real and small, and it is handled the same way the SSRI warning is handled: a conversation before starting, closer contact in the first weeks, and a low threshold for calling. Rare severe liver injury has been reported, on the order of a few cases per million patient-years; routine liver testing is not recommended, but jaundice, dark urine, or right-upper-quadrant pain warrant stopping the drug and checking. Heart rate and blood pressure rise modestly and should be measured at baseline and at follow-up, as with stimulants.

Limitations of this comparison

This comparison has several limitations. First, the effect sizes come from a network meta-analysis of placebo-controlled trials rather than head-to-head trials; only a handful of direct atomoxetine-versus-stimulant trials exist, and none compare atomoxetine with viloxazine. Second, the trials measured core symptoms over six to twelve weeks, whereas the decision in clinic is about function over years. Third, viloxazine was approved after the 2018 analysis, so its position in the table rests on registration trials and indirect estimates. Nevertheless, the rank order (stimulants, then the alpha-2 agonists and norepinephrine reuptake inhibitors in a lower band) has been stable across every meta-analysis since 2010, and it is a reliable starting point for the conversation.

Frequently Asked Questions

Is Strattera a stimulant?

No. Strattera (atomoxetine) is a selective norepinephrine reuptake inhibitor and was the first non-stimulant the FDA approved for ADHD, in 2002. It is not a controlled substance, it has no abuse liability in the way amphetamine and methylphenidate do, and it works continuously rather than in a daily peak-and-trough pattern. It takes roughly four to eight weeks at a therapeutic dose to reach full effect.

Strattera vs Intuniv: which is better for ADHD?

They act on different targets and suit different patients. In the Cortese 2018 Lancet Psychiatry network meta-analysis of children and adolescents, guanfacine (Intuniv) had a standardized effect size of about 0.67 and atomoxetine about 0.56, with overlapping confidence intervals. Intuniv tends to help more with hyperactivity, impulsivity, irritability, and sleep-onset problems, and is FDA-approved as an add-on to a stimulant. Strattera tends to suit inattention with comorbid anxiety, and it is approved for adults, which Intuniv is not.

Strattera vs Qelbree: what is the difference?

Both are norepinephrine reuptake inhibitors with a boxed warning for suicidal thoughts in young people. Qelbree (viloxazine extended-release) was approved in 2021 for ages 6-17 and in 2022 for adults; its onset is often somewhat faster (improvement within one to two weeks in trials), and it is not metabolized by CYP2D6, so it avoids the poor-metabolizer problem that affects a minority of Strattera patients. Qelbree is a strong CYP1A2 inhibitor and interacts with caffeine, some antidepressants, and clozapine. Strattera has generic pricing and two decades of long-term data; Qelbree does not yet.

What are the alternatives to Strattera?

Within non-stimulants: viloxazine (Qelbree), guanfacine extended-release (Intuniv), and clonidine extended-release (Kapvay). Off-label, bupropion has modest evidence in adults (effect size around 0.46 in Cortese 2018). Stimulants remain the most effective class, with amphetamines near 1.0 and methylphenidate near 0.8 in children, so for most patients without a contraindication the alternative to a non-stimulant that has not worked is a properly titrated stimulant.

How long does Strattera take to work?

Some patients notice change within two weeks, but the registration trials and clinical experience both put the full effect at four to eight weeks on a therapeutic dose, typically 1.2 mg/kg/day in children (maximum 1.4 mg/kg or 100 mg). Stopping at three weeks because it is not working yet is the most common reason atomoxetine fails.

Can you take Strattera with a stimulant?

Yes, and the combination is used clinically when a stimulant controls the core symptoms but coverage is short or evenings are difficult. The combination is off-label, raises heart rate and blood pressure additively, and should be monitored. Guanfacine extended-release is the only non-stimulant with an FDA-approved adjunctive indication alongside stimulants.

Primary references

• Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738.
• Strattera (atomoxetine) prescribing information, Eli Lilly; Intuniv (guanfacine extended-release) prescribing information, Takeda; Qelbree (viloxazine extended-release) prescribing information, Supernus.
• Bymaster FP, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat. Neuropsychopharmacology. 2002;27(5):699-711.
• FDA Public Health Advisory on atomoxetine and suicidal thinking, September 2005.

Further reading

• Non-Stimulant ADHD Meds: Do They Actually Work? — the class-level question.
• New ADHD Medications 2026 — Qelbree, Simtriyo, and the rest of the pipeline.
• ADHD with Tics — when stimulants are still usable.
• ADHD Medication Titration — how a stimulant trial is actually run.
• ADHD Psychiatrist NYC — Dr. Sultan's clinical practice for evaluation and medication management.

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Medication decisions belong in a conversation with a qualified prescriber who knows your history.